Author: admin

DelveInsight’s “Cerebral Palsy Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Cerebral Palsy, historical and forecasted epidemiology as well as the Cerebral Palsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Cerebral Palsy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cerebral Palsy Market Forecast

Some of the key facts of the Cerebral Palsy Market Report:

• The Cerebral Palsy market size is anticipated to grow with a significant CAGR during the study period (2022-2036)

• In March 2025, GeneDx (Nasdaq: WGS), a leading provider of genomic insights for better health outcomes, has announced the expansion of its genetic testing services to include cerebral palsy (CP). Timed with Cerebral Palsy Awareness Month, this initiative broadens the company’s focus on pediatric rare diseases by offering testing for children with CP. The expansion highlights the importance of enhancing access to exome and genome testing, aiming to reduce diagnostic delays and expedite treatment pathways for CP patients.

• Cerebral palsy is the most common motor disability in childhood. Several population-based studies worldwide report prevalence estimates ranging from 1 to nearly 4 cases per 1,000 live births or per 1,000 children.

• Dyskinetic cerebral palsy is the second most common subtype after spastic forms, while ataxic cerebral palsy is the least common type and is characterized by uncoordinated and jerky movements.

• Spastic cerebral palsy is the most prevalent subtype, accounting for approximately 71–82% of all cerebral palsy cases, with prevalence estimates ranging from 2.6 to 3.0 cases per 1,000 children.

• Children and adolescents with Cerebral Palsy are at increased risk of fragility fractures, particularly in non-weight-bearing patients, with higher fracture risk observed in those with severe growth impairment or receiving antiepileptic therapy.

• Studies report an annual fracture incidence of ~4% among children and adolescents with non-ambulatory Cerebral Palsy, with more than 75% of fractures occurring in the lower extremities.

• In France, cerebral palsy affects approximately 2 per 1,000 newborns, corresponding to nearly 1,500 new cases annually. Prevalence increases to approximately 5–8% among very preterm infants or those with very low birth weight.

• Key Cerebral Palsy Companies: Ipsen, Abbvie (Allergan), Supernus Pharmaceuticals, Neurocrine Biosciences, Teva Pharmaceuticals, Bundang CHA Hospital, Jazz Pharmaceuticals, Stanford University, Teva Branded Pharmaceutical, Merz Pharmaceuticals GmbH, Rohto Pharmaceutical Co., Ltd., Shionogi, and others

• Key Cerebral Palsy Therapies: DYSPORT (abobotulinumtoxin A), Botox (Onabotulinum toxin A), MYOBLOC (RimabotulinumtoxinB), VALBENAZINE, AUSTEDO, Erythropoietin, Sativex, Botulinum Toxin type B, TEV-50717, IncobotulinumtoxinA, UDI-001, Oral Glycopyrrolate Liquid, and others

• The Cerebral Palsy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cerebral Palsy pipeline products will significantly revolutionize the Cerebral Palsy market dynamics.

Cerebral Palsy Overview

Cerebral Palsy comprises a collection of conditions impacting movement, muscle tone, and posture. The condition arises from damage to the developing brain, typically occurring before birth, which can affect motor function control. Those affected may experience challenges with both voluntary and involuntary movements, leading to unsteady or lax motions.

Get a Free sample for the Cerebral Palsy Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/cerebral-palsy-market

Cerebral Palsy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cerebral Palsy Epidemiology Segmentation:

The Cerebral Palsy market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of Chronic Insomnia

• Type-specific Diagnosed Prevalent Cases of Chronic Insomnia

• Gender-specific Diagnosed Prevalent Cases of Chronic Insomnia

• Age-specific Diagnosed Prevalent Cases of Chronic Insomnia

Download the report to understand which factors are driving Cerebral Palsy epidemiology trends @ Cerebral Palsy Epidemiology Forecast

Cerebral Palsy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cerebral Palsy market or expected to get launched during the study period. The analysis covers Cerebral Palsy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cerebral Palsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cerebral Palsy Therapies and Key Companies

• DYSPORT (abobotulinumtoxin A): Ipsen

• Botox (Onabotulinum toxin A): Abbvie (Allergan)

• MYOBLOC (RimabotulinumtoxinB): Supernus Pharmaceuticals

• VALBENAZINE: Neurocrine Biosciences

• AUSTEDO: Teva Pharmaceuticals

• Erythropoietin: Bundang CHA Hospital

• Sativex: Jazz Pharmaceuticals

• Botulinum Toxin type B: Stanford University

• TEV-50717: Teva Branded Pharmaceutical

• IncobotulinumtoxinA: Merz Pharmaceuticals GmbH

• UDI-001: Rohto Pharmaceutical Co., Ltd.

• Oral Glycopyrrolate Liquid: Shionogi

Discover more about therapies set to grab major Cerebral Palsy market share @ Cerebral Palsy Treatment Landscape

Cerebral Palsy Market Drivers

• Increasing prevalence of cerebral palsy and improved survival rates among premature infants are expanding the patient population requiring long-term care.

• Advancements in rehabilitation therapies, assistive technologies, and mobility devices are improving patient outcomes and driving market growth.

• Growing awareness and early diagnosis initiatives are enabling timely intervention and treatment.

• Rising investment in regenerative medicine, stem cell research, and neurodevelopmental therapies is creating new opportunities in the treatment landscape.

Cerebral Palsy Market Barriers

• Limited availability of disease-modifying therapies, with most current treatments focused on symptom management rather than cure.

• High treatment and rehabilitation costs can place a significant financial burden on patients and caregivers.

• Variability in disease severity and clinical presentation complicates treatment standardization and clinical trial design.

• Restricted access to specialized care and rehabilitation services in developing regions may hinder market growth.

Scope of the Cerebral Palsy Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Cerebral Palsy Companies: Ipsen, Abbvie (Allergan), Supernus Pharmaceuticals, Neurocrine Biosciences, Teva Pharmaceuticals, Bundang CHA Hospital, Jazz Pharmaceuticals, Stanford University, Teva Branded Pharmaceutical, Merz Pharmaceuticals GmbH, Rohto Pharmaceutical Co., Ltd., Shionogi, and others

• Key Cerebral Palsy Therapies: DYSPORT (abobotulinumtoxin A), Botox (Onabotulinum toxin A), MYOBLOC (RimabotulinumtoxinB), VALBENAZINE, AUSTEDO, Erythropoietin, Sativex, Botulinum Toxin type B, TEV-50717, IncobotulinumtoxinA, UDI-001, Oral Glycopyrrolate Liquid, and others

• Cerebral Palsy Therapeutic Assessment: Cerebral Palsy current marketed and Cerebral Palsy emerging therapies

• Cerebral Palsy Market Dynamics: Cerebral Palsy market drivers and Cerebral Palsy market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Cerebral Palsy Unmet Needs, KOL’s views, Analyst’s views, Cerebral Palsy Market Access and Reimbursement

To know more about Cerebral Palsy companies working in the treatment market, visit @ Cerebral Palsy Clinical Trials and Therapeutic Assessment

Table of Contents

1. Cerebral Palsy Market Report Introduction

2. Executive Summary for Cerebral Palsy

3. SWOT analysis of Cerebral Palsy

4. Cerebral Palsy Patient Share (%) Overview at a Glance

5. Cerebral Palsy Market Overview at a Glance

6. Cerebral Palsy Disease Background and Overview

7. Cerebral Palsy Epidemiology and Patient Population

8. Country-Specific Patient Population of Cerebral Palsy

9. Cerebral Palsy Current Treatment and Medical Practices

10. Cerebral Palsy Unmet Needs

11. Cerebral Palsy Emerging Therapies

12. Cerebral Palsy Market Outlook

13. Country-Wise Cerebral Palsy Market Analysis (2022–2036)

14. Cerebral Palsy Market Access and Reimbursement of Therapies

15. Cerebral Palsy Market Drivers

16. Cerebral Palsy Market Barriers

17. Cerebral Palsy Appendix

18. Cerebral Palsy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cerebral Palsy Market Positioned for Significant Commercial Growth by 2036 – DelveInsight | Neurocrine Biosciences, Teva Pharma, Bundang CHA Hospital, Jazz Pharma

DelveInsight’s “Anal Fistula Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Anal Fistula, historical and forecasted epidemiology as well as the Anal Fistula market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Anal Fistula, offering comprehensive insights into the Anal Fistula revenue trends, prevalence, and treatment landscape. The report delves into key Anal Fistula statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Anal Fistula therapies. Additionally, we cover the landscape of Anal Fistula clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Anal Fistula treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Anal Fistula space.

Get a Free sample for the Anal Fistula Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/anal-fistula-market

Some of the key facts of the Anal Fistula Market Report:

• The Anal Fistula market size was valued at around USD 12 million in 2025 and is anticipated to grow to nearly USD 120 million by 2036, registering a robust CAGR of 24% between 2026 and 2036.

• In October 2025, Oncolytics Biotech announced updated clinical data for Pelareorep in combination with atezolizumab in previously treated metastatic Anal Fistula, demonstrating an objective response rate of ~30%, which was more than double historical response rates seen with currently available therapies.

• In October 2025, Avobis Bio Therapeutics announced that the US FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to AVB-114 for Crohn’s perianal fistulas. The designation followed encouraging Phase II findings and strengthened regulatory interactions supporting future Phase III development planning.

• In August 2025, Avobis Bio Therapeutics completed the primary analysis of the STOMP-II Phase II trial evaluating AVB-114 in Crohn’s perianal fistulas. The company reported that the findings supported an RMAT submission and highlighted continued advancement of implantable regenerative therapies for complex fistulizing disease.

• In August 2025, Invion Limited announced that the US FDA granted Orphan Drug Designation to INV043 for the treatment of Anal Fistula, providing incentives to support the development of this therapy for a rare disease.

• In May 2025, Incyte announced that the FDA had approved ZYNYZ, making it the first and only approved first-line treatment for advanced Anal Fistula patients in the US. In addition, the FDA approved ZYNYZ as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.

• In February 2025, Avobis Bio Therapeutics Fast Track Update announced that the US FDA granted Fast Track designation to AVB-114 for Crohn’s perianal fistulas based on positive Phase I STOMP-I findings, reflecting increasing regulatory support for regenerative treatment approaches in refractory fistulizing disease.

• Chemoradiotherapy (CRT) remains the standard of care for localized Anal Fistula, with ongoing research focusing on targeted therapies, immunotherapies, and novel chemotherapeutic agents to improve treatment outcomes.

• Nivolumab (OPDIVO) and pembrolizumab (KEYTRUDA) are considered second-line immunotherapy options for patients who do not respond to initial treatments.

• According to DelveInsight’s estimates, in 2025, there were nearly 20,500 incident cases of Anal Fistula in the 7MM, out of which the US accounted for the highest incident cases in 2025.

• In EU4 and the UK, females accounted for more incident cases of Anal Fistula, i.e., nearly 70%, as compared to males with incident cases of nearly 30%, in 2025.

• In 2025, among EU4 and the UK, Germany accounted for the highest number of cases of Anal Fistula, whereas Spain accounted for the least number of cases.

• As per the analysis, in the United States in 2025, Anal Fistula was found to be more incident in patients aged 65 years and above (~60%), followed by patients aged 50-64 years (~37%), and it was lowest in patients below 50 years (~4%).

• In 2025, Japan accounted for approximately 1,200 incident cases of Anal Fistula accounted for approximately, which was significantly lower compared to the EU4 and the US.

• In Japan, HPV negative (~1, 100 cases) cases of Anal Fistula were found to be more incident than HPV positive (~100 cases) in 2025

• Key Anal Fistula Companies: Avobis Bio Therapeutics, Stempeutics Research, and others.

• Key Anal Fistula Therapies: AVB-114, Stempeucel, and others

• The epidemiology of Anal Fistula is segmented based on underlying etiologies and disease characteristics, including cryptoglandular fistulas, fistulas associated with Crohn’s Disease, recurrent fistulas, and complex fistulizing disease. The patient population is further categorized into diagnosed cases, fistula complexity-specific cases, recurrence-based populations, and treated patient pools across the 7MM.

• The prevalence of Anal Fistula continues to increase globally, primarily driven by rising incidence of anorectal abscesses, increasing prevalence of inflammatory bowel diseases, improved disease recognition, and expanding access to specialist colorectal care. Adults in younger and middle-aged populations represent a substantial proportion of affected patients.

• Male patients account for a larger proportion of the Anal Fistula population compared with females, with epidemiological studies consistently demonstrating a higher incidence among men, potentially due to differences in anorectal gland anatomy and disease susceptibility patterns.

• Anal fistula is a relatively uncommon but clinically significant anorectal disorder, with reported incidence ranging from approximately 1–8 cases per 10,000 individuals annually, contributing a substantial healthcare burden due to recurrence and need for repeated interventions.

• Anal fistula demonstrates a clear male predominance, with incidence estimates of approximately 12.3 per 100,000 in men versus 5.6 per 100,000 in women, indicating nearly a two-fold greater disease burden among males.

Anal Fistula Overview

Anal Fistula is a rare type of cancer that develops in the tissues of the anus, the opening at the end of the rectum. It often begins in the squamous cells lining the anal canal. Risk factors include human papillomavirus (HPV) infection, smoking, weakened immune system, and a history of anal or genital warts. Symptoms may include bleeding, pain, itching, or a lump near the anus. Treatment options typically involve surgery, radiation therapy, and chemotherapy, depending on the stage and spread of the cancer. Early detection significantly improves outcomes.

To Know in detail about the Anal Fistula market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Anal Fistula Market Forecast

Anal Fistula Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Anal Fistula Epidemiology Segmentation:

The Anal Fistula market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of Anal Fistula

• Gender-specific Diagnosed Prevalent Cases of Anal Fistula

• Age-specific Diagnosed Prevalent Cases of Anal Fistula

• Type-specific Diagnosed Prevalent Cases of Anal Fistula

• Treated Cases of Anal Fistula

Download the report to understand which factors are driving Anal Fistula epidemiology trends @ Anal Fistula Epidemiology Forecast

Anal Fistula Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Anal Fistula market or expected to get launched during the study period. The analysis covers Anal Fistula market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Anal Fistula Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Anal Fistula Therapies and Key Companies

• AVB-114: Avobis Bio Therapeutics

• Stempeucel: Stempeutics Research

Discover more about therapies set to grab major Anal Fistula market share @ Anal Fistula Treatment Landscape

Anal Fistula Market Drivers

• Increasing incidence of HPV-associated Anal Fistula, particularly among high-risk populations, is driving demand for effective treatment options.

• Growing awareness and improved screening practices are facilitating earlier diagnosis and increasing the number of patients entering treatment pathways.

• Advancements in immunotherapy and targeted therapies are expanding treatment options for advanced and recurrent Anal Fistula.

• Rising investment in oncology research and clinical trials is accelerating the development of novel therapeutics for Anal Fistula.

Anal Fistula Market Barriers

• Relatively low disease prevalence compared to other cancers limits patient populations and may reduce commercial incentives for drug development.

• Limited availability of approved targeted therapies restricts treatment choices, particularly for advanced or metastatic disease.

• Challenges in early detection and diagnosis can lead to delayed treatment and poorer clinical outcomes.

• High treatment costs and reimbursement constraints may hinder access to novel therapies in certain regions.

Scope of the Anal Fistula Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Anal Fistula Companies: Avobis Bio Therapeutics, Stempeutics Research, and others

• Key Anal Fistula Therapies: AVB-114, Stempeucel, and others

• Anal Fistula Therapeutic Assessment: Anal Fistula current marketed and Anal Fistula emerging therapies

• Anal Fistula Market Dynamics: Anal Fistula market drivers and Anal Fistula market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Anal Fistula Unmet Needs, KOL’s views, Analyst’s views, Anal Fistula Market Access and Reimbursement

To know more about Anal Fistula companies working in the treatment market, visit @ Anal Fistula Clinical Trials and Therapeutic Assessment

Table of Contents

1. Anal Fistula Market Report Introduction

2. Executive Summary for Anal Fistula

3. SWOT analysis of Anal Fistula

4. Anal Fistula Patient Share (%) Overview at a Glance

5. Anal Fistula Market Overview at a Glance

6. Anal Fistula Disease Background and Overview

7. Anal Fistula Epidemiology and Patient Population

8. Country-Specific Patient Population of Anal Fistula

9. Anal Fistula Current Treatment and Medical Practices

10. Anal Fistula Unmet Needs

11. Anal Fistula Emerging Therapies

12. Anal Fistula Market Outlook

13. Country-Wise Anal Fistula Market Analysis (2022–2036)

14. Anal Fistula Market Access and Reimbursement of Therapies

15. Anal Fistula Market Drivers

16. Anal Fistula Market Barriers

17. Anal Fistula Appendix

18. Anal Fistula Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Anal Fistula Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Avobis Bio Therapeutics, Stempeutics Research

DelveInsight’s “Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Metastatic Prostate Cancer, historical and forecasted epidemiology as well as the Metastatic Prostate Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Get a Free sample for the Metastatic Prostate Cancer Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/metastatic-prostate-cancer-market

Some of the key facts of the Metastatic Prostate Cancer Market Report:

• The metastatic prostate cancer market size is estimated at approximately USD 11,500 million in 2025 and is projected to grow at a significant CAGR during 2026–2036.

• In June 2025, Johnson & Johnson, a US-based pharmaceutical firm, has released Phase I trial data for its bispecific antibody, pasritamig, targeting metastatic castration-resistant prostate cancer (mCRPC). The first-in-human study involved 174 participants aged 36 to 89, who had previously received an average of four treatments. Findings from the trial showed that pasritamig was well-tolerated and exhibited promising anti-tumor activity in patients with mCRPC.

• In May 2025, Janux Therapeutics initiated Phase Ib expansion studies of JANX007 as part of the ongoing first-in-human ENGAGER-PSMA-01 clinical trial, targeting patients with advanced metastatic castration-resistant prostate cancer (mCRPC). This open-label, multicenter Phase I trial is designed to evaluate the tolerability, safety, pharmacodynamics, pharmacokinetics, and preliminary efficacy of JANX007, either as a monotherapy or in combination therapy, in adult patients with advanced mCRPC. The initial Phase Ib segment will enroll taxane-naïve mCRPC patients, focusing on those in first-line (1L) and second-line (2L) treatment settings. Two dosing regimens—0.3/2/6mg and 0.3/2/9mg—of JANX007 monotherapy are being assessed for their safety and effectiveness.

• In May 2025, Astellas and Pfizer have shared five-year follow-up results from the open-label extension of the Phase III ARCHES trial. The findings revealed that Xtandi (enzalutamide), when used in combination with androgen deprivation therapy (ADT), led to a 30% reduction in the risk of death in men with metastatic hormone-sensitive prostate cancer (mHSPC). Patients receiving this combination therapy demonstrated improved survival outcomes compared to those treated with placebo plus ADT.

• In March 2025, The FDA has granted approval to Novartis’ radioligand therapy, Pluvicto (lutetium Lu 177 vipivotide tetraxetan), for use in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have already undergone treatment with an androgen receptor pathway inhibitor (ARPI) and are suitable candidates for postponing chemotherapy.

• In March 2025, MacroGenics is discontinuing the development of one of its antibody-drug conjugates (ADC) following disappointing results in a Phase II prostate cancer study. The Rockville, Maryland-based biotech announced that trials of vobramitamab duocarmazine (vobra duo) will be halted, as the safety and efficacy data from the TAMARACK Phase II study (NCT05551117) did not justify further financial investment.

• In March 2025, Janux Therapeutics initiated Phase Ib expansion studies of JANX007 in the first-in-human ENGAGER-PSMA-01 clinical trial targeting advanced metastatic castration-resistant prostate cancer (mCRPC). This open-label, multicenter Phase I trial aims to evaluate the tolerability, pharmacodynamics, safety, preliminary efficacy, and pharmacokinetics of JANX007 as a standalone treatment or in combination therapy for adults with advanced mCRPC.

• According to DelveInsight’s estimates, in 2025, the total number of prevalent cases of metastatic prostate cancer in the 7MM were ~315,000.

• Based on DelveInsight’s assessment in 2025, the US had ~3,864,000 prevalent cases of prostate cancer. These are expected to rise due to the growing geriatric population and advancements in diagnostic capabilities during the forecast period (2026−2036).

• The five-year prevalent cases of prostate cancer in the US was approximately ~1,157,000 in 2025.

• In 2025, in the US, the total cases of mCSPC were approximately ~72,500.

• According to the SEER, prostate cancer is most frequently diagnosed among men aged 65–74 years; the median age at diagnosis is 66 years. The most number of cases was found in people aged between 65 and 74 years, followed by 55–64 years and 75–84 years.

• The market is experiencing strong expansion in genomically targeted therapies, particularly PARP inhibitors such as Olaparib (LYNPARZA), Talazoparib (TALZENNA), and the combination of abiraterone acetate/niraparib (AKEEGA) for patients with HRR/BRCA-mutated metastatic castration-resistant prostate cancer. Concurrently, the growing adoption of molecular diagnostics and PSMA imaging is enhancing patient stratification and is expected to further accelerate the uptake of targeted treatment options over the forecast period.

• Key Metastatic Prostate Cancer Companies: Curium US LLC, Bayer, Hookipa Biotech GmbH, University Health Network, Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharmaceuticals, Mark Stein, Novartis, Orion Corporation, Janssen Research & Development, AstraZeneca, MedSIR, Aragon Pharmaceuticals, Janssen Research & Development, Telix Pharmaceuticals, Alliance Foundation Trials, Epizyme, Inc., Exelixis, and others

• Key Metastatic Prostate Cancer Therapies: 177Lu-PSMA-I&T, Darolutamide (Nubeqa, BAY1841788), HB-302/HB-301, Enzalutamide, Opevesostat, Pembrolizumab, ARV-766 Part A&B, Darolutamide, Apalutamide, REGN2810, 177Lu-PSMA-617, ODM-208, Apalutamide, AZD0754, Enzalutamide, Apalutamide, Niraparib, 177Lu-DOTA-rosopatamb, Darolutamide, Tazemetostat, Cabozantinib, and others

• The Metastatic Prostate Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic Prostate Cancer pipeline products will significantly revolutionize the Metastatic Prostate Cancer market dynamics.

Metastatic Prostate Cancer Overview

Metastatic prostate cancer is an advanced stage of prostate cancer in which the cancer cells have spread beyond the prostate gland to other parts of the body, most commonly the bones, lymph nodes, liver, or lungs. This occurs when cancer cells break away from the original tumor and travel through the bloodstream or lymphatic system. Symptoms may include bone pain, fatigue, weight loss, and difficulty urinating. While it is not curable, treatments like hormone therapy, chemotherapy, targeted therapy, and radiation can help manage symptoms and slow disease progression.

To Know in detail about the Metastatic Prostate Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metastatic Prostate Cancer Market Forecast

Metastatic Prostate Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Metastatic Prostate Cancer Epidemiology Segmentation:

The Metastatic Prostate Cancer market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Prevalent Cases of Prostate Cancer

• Five-year Prevalent Cases of Prostate Cancer

• Total Prevalent Cases of Prostate Cancer Cases by Clinical Stages

• Age-specific Cases of Prostate Cancer

• Total Prevalent Cases of Metastatic Prostate Cancer

Download the report to understand which factors are driving Metastatic Prostate Cancer epidemiology trends @ Metastatic Prostate Cancer Epidemiology Forecast

Metastatic Prostate Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Prostate Cancer market or expected to get launched during the study period. The analysis covers Metastatic Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Metastatic Prostate Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Metastatic Prostate Cancer Therapies and Key Companies

• 177Lu-PSMA-I&T: Curium US LLC

• Darolutamide (Nubeqa, BAY1841788): Bayer

• HB-302/HB-301: Hookipa Biotech GmbH

• Enzalutamide: University Health Network

• Opevesostat: Merck Sharp & Dohme

• Pembrolizumab: Merck Sharp & Dohme

• ARV-766 Part A&B: Arvinas Androgen Receptor

• Darolutamide: UNICANCER

• Apalutamide: Aragon Pharmaceuticals

• REGN2810: Mark Stein

• 177Lu-PSMA-617: Novartis

• ODM-208: Orion Corporation, Orion Pharma

• Apalutamide: Janssen Research & Development

• AZD0754: AstraZeneca

• Enzalutamide: MedSIR

• Apalutamide: Aragon Pharmaceuticals

• Niraparib: Janssen Research & Development

• 177Lu-DOTA-rosopatamb: Telix Pharmaceuticals

• Darolutamide: Alliance Foundation Trials

• Tazemetostat: Epizyme, Inc.

• Cabozantinib: Exelixis

Discover more about therapies set to grab major Metastatic Prostate Cancer market share @ Metastatic Prostate Cancer Treatment Landscape

Metastatic Prostate Cancer Market Drivers

• Rising incidence of prostate cancer and an aging population are increasing the number of patients progressing to metastatic disease.

• Advancements in targeted therapies, androgen receptor inhibitors, radioligand therapies, and immunotherapies are expanding treatment options and improving outcomes.

• Growing adoption of precision medicine and biomarker-based testing is enabling more personalized treatment approaches.

• Increased awareness, early diagnosis, and improved screening practices are supporting better disease management.

Metastatic Prostate Cancer Market Barriers

• High treatment costs associated with advanced therapies may limit patient access and place pressure on healthcare systems.

• Development of treatment resistance, particularly in metastatic castration-resistant prostate cancer (mCRPC), remains a significant clinical challenge.

• Adverse effects and safety concerns linked to long-term therapy can affect treatment adherence.

• Stringent regulatory requirements and lengthy clinical development timelines may delay the introduction of new therapies.

Scope of the Metastatic Prostate Cancer Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Metastatic Prostate Cancer Companies: Curium US LLC, Bayer, Hookipa Biotech GmbH, University Health Network, Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharmaceuticals, Mark Stein, Novartis, Orion Corporation, Janssen Research & Development, AstraZeneca, MedSIR, Aragon Pharmaceuticals, Janssen Research & Development, Telix Pharmaceuticals, Alliance Foundation Trials, Epizyme, Inc., Exelixis, and others

• Key Metastatic Prostate Cancer Therapies: 177Lu-PSMA-I&T, Darolutamide (Nubeqa, BAY1841788), HB-302/HB-301, Enzalutamide, Opevesostat, Pembrolizumab, ARV-766 Part A&B, Darolutamide, Apalutamide, REGN2810, 177Lu-PSMA-617, ODM-208, Apalutamide, AZD0754, Enzalutamide, Apalutamide, Niraparib, 177Lu-DOTA-rosopatamb, Darolutamide, Tazemetostat, Cabozantinib, and others

• Metastatic Prostate Cancer Therapeutic Assessment: Metastatic Prostate Cancer current marketed and Metastatic Prostate Cancer emerging therapies

• Metastatic Prostate Cancer Market Dynamics: Metastatic Prostate Cancer market drivers and Metastatic Prostate Cancer market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Metastatic Prostate Cancer Unmet Needs, KOL’s views, Analyst’s views, Metastatic Prostate Cancer Market Access and Reimbursement

To know more about Metastatic Prostate Cancer companies working in the treatment market, visit @ Metastatic Prostate Cancer Clinical Trials and Therapeutic Assessment

Table of Contents

1. Metastatic Prostate Cancer Market Report Introduction

2. Executive Summary for Metastatic Prostate Cancer

3. SWOT analysis of Metastatic Prostate Cancer

4. Metastatic Prostate Cancer Patient Share (%) Overview at a Glance

5. Metastatic Prostate Cancer Market Overview at a Glance

6. Metastatic Prostate Cancer Disease Background and Overview

7. Metastatic Prostate Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Metastatic Prostate Cancer

9. Metastatic Prostate Cancer Current Treatment and Medical Practices

10. Metastatic Prostate Cancer Unmet Needs

11. Metastatic Prostate Cancer Emerging Therapies

12. Metastatic Prostate Cancer Market Outlook

13. Country-Wise Metastatic Prostate Cancer Market Analysis (2022–2036)

14. Metastatic Prostate Cancer Market Access and Reimbursement of Therapies

15. Metastatic Prostate Cancer Market Drivers

16. Metastatic Prostate Cancer Market Barriers

17. Metastatic Prostate Cancer Appendix

18. Metastatic Prostate Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Prostate Cancer Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Merck, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis, Orion Corp

DelveInsight’s “Alpha Thalassemia Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Alpha Thalassemia, historical and forecasted epidemiology as well as the Alpha Thalassemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Alpha Thalassemia, offering comprehensive insights into the Alpha Thalassemia revenue trends, prevalence, and treatment landscape. The report delves into key Alpha Thalassemia statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Alpha Thalassemia therapies. Additionally, we cover the landscape of Alpha Thalassemia clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Alpha Thalassemia treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Alpha Thalassemia space.

Get a Free sample for the Alpha Thalassemia Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/alpha-thalassemia-market

Some of the key facts of the Alpha Thalassemia Market Report:

• The Alpha Thalassemia market size was valued ~USD 150 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2022-2036).

• In December 2025, Agios Pharmaceuticals (AGIO) announced that the FDA has not yet issued a decision on the company’s supplemental new drug application (sNDA) for its marketed therapy, Pyrukynd (mitapivat), for thalassemia. The application seeks approval to expand Pyrukynd’s use to adult patients with both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia.

• In December 2025, Genetix Biotherapeutics Inc. announced its selection to participate in the American Society of Hematology’s (ASH) exclusive press program ahead of the 67th ASH Annual Meeting, scheduled in Orlando, Florida, from December 6–9, 2025. The company’s abstract, “Accelerating access to gene therapy: Lessons from commercial implementation in sickle cell disease and transfusion-dependent thalassemia,” was chosen by the ASH Program Committee as one of the most impactful datasets submitted this year.

• In June 2025, Agios Pharmaceuticals presented new data on the company’s PK activators, mitapivat and tebapivat, will be featured in oral and poster presentations during the 30th EHA Congress 2025.

• In January 2025, Agios Pharmaceuticals (AGIO) announced that the FDA has accepted its supplemental new drug application (sNDA) for label expansion of Pyrukynd, its only marketed drug, for the treatment of thalassemia.

• Key Alpha Thalassemia Companies: Forma Therapeutics, Inc., Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharmaceuticals, and others

• Key Alpha Thalassemia Therapies: Etavopivat tablets, GMCN-508A, Luspatercept, Mitapivat, and others

• About 300 million people around the world have the “thalassemia trait”, which puts them at risk of having children with some form of thalassemia. More than 1 million people have non-transfusion-dependent thalassemia, while more than 100,000 people have transfusion-dependent thalassemia. In the US, there are at least 1,200 people with transfusion-dependent thalassemia.

• Worldwide, at least 300,000 children are born each year affected with a severe form of hemoglobinopathy. Furthermore, at least 20% of the global population carries at least a single gene deletion for alpha thalassemia.

• Roughly 56,000 children are born annually with severe alpha or beta thalassemia, of whom more than half require regular transfusions, and 5500 die perinatally due to alpha thalassemia major (hydrops fetalis).

• Over half of alpha-thalassemia cases in Japan are of Southeast Asian origin, while the rest involve unique, largely undetermined Japanese mutations, indicating a dual origin. Beta-thalassemia occurs in about 1 in 600–1,000 people, and alpha(+)-thalassemia (-a/) in about 1 in 400, making alpha-thal trait (-a/-a) extremely rare.

Alpha Thalassemia Overview

Alpha thalassemia is a genetic blood disorder caused by mutations in the genes responsible for producing alpha-globin, a component of hemoglobin. Hemoglobin is essential for carrying oxygen throughout the body, and a deficiency in alpha-globin leads to abnormal red blood cells and reduced oxygen transport. The condition ranges in severity, from silent carriers with no symptoms to severe forms like Hemoglobin H disease and alpha thalassemia major, which can cause life-threatening anemia. Common symptoms include fatigue, pale skin, and growth delays. Treatment depends on severity and may include blood transfusions, iron chelation therapy, or bone marrow transplantation.

To Know in detail about the Alpha Thalassemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alpha Thalassemia Market Forecast

Alpha Thalassemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Alpha Thalassemia Epidemiology Segmentation:

The Alpha Thalassemia market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of Thalassemia

• Total Diagnosed Prevalent Cases of Alpha-thalassemia

• Total Diagnosed Prevalent Cases of Alpha-thalassemia based on Transfusion Requirement

• Total Treatable Cases of Alpha-thalassemia

Download the report to understand which factors are driving Alpha Thalassemia epidemiology trends @ Alpha Thalassemia Epidemiology Forecast

Alpha Thalassemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alpha Thalassemia market or expected to get launched during the study period. The analysis covers Alpha Thalassemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Alpha Thalassemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Alpha Thalassemia Therapies and Key Companies

• PYRUKYND (mitapivat): Agios Pharmaceuticals

• Etavopivat tablets: Forma Therapeutics, Inc.

• GMCN-508A: Genmedicn Biopharma Ltd.

• Luspatercept: Bristol-Myers Squibb

• Mitapivat: Agios Pharmaceuticals

Discover more about therapies set to grab major Alpha Thalassemia market share @ Alpha Thalassemia Treatment Landscape

Alpha Thalassemia Market Drivers

• Increasing Prevalence genetic disorders and advancement in healthcare technologies, growing demand for treatment for Alpha Thalassemia are some of the important factors that are fueling the Alpha Thalassemia Market.

Alpha Thalassemia Market Barriers

• However, lack of available appropriate treatments and procedures, high cost of treatment and other factors are creating obstacles in the Alpha Thalassemia Market growth.

Scope of the Alpha Thalassemia Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Alpha Thalassemia Companies: Forma Therapeutics, Inc., Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharmaceuticals, and others

• Key Alpha Thalassemia Therapies: Etavopivat tablets, GMCN-508A, Luspatercept, Mitapivat, and others

• Alpha Thalassemia Therapeutic Assessment: Alpha Thalassemia current marketed and Alpha Thalassemia emerging therapies

• Alpha Thalassemia Market Dynamics: Alpha Thalassemia market drivers and Alpha Thalassemia market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Alpha Thalassemia Unmet Needs, KOL’s views, Analyst’s views, Alpha Thalassemia Market Access and Reimbursement

To know more about Alpha Thalassemia companies working in the treatment market, visit @ Alpha Thalassemia Clinical Trials and Therapeutic Assessment

Table of Contents

1. Alpha Thalassemia Market Report Introduction

2. Executive Summary for Alpha Thalassemia

3. SWOT analysis of Alpha Thalassemia

4. Alpha Thalassemia Patient Share (%) Overview at a Glance

5. Alpha Thalassemia Market Overview at a Glance

6. Alpha Thalassemia Disease Background and Overview

7. Alpha Thalassemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Alpha Thalassemia

9. Alpha Thalassemia Current Treatment and Medical Practices

10. Alpha Thalassemia Unmet Needs

11. Alpha Thalassemia Emerging Therapies

12. Alpha Thalassemia Market Outlook

13. Country-Wise Alpha Thalassemia Market Analysis (2022–2036)

14. Alpha Thalassemia Market Access and Reimbursement of Therapies

15. Alpha Thalassemia Market Drivers

16. Alpha Thalassemia Market Barriers

17. Alpha Thalassemia Appendix

18. Alpha Thalassemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alpha Thalassemia Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Forma Therapeutics, Genmedicn Biopharma, Bristol-Myers Squibb, Agios Pharma